Susan Schneider, MD serves as Senior Vice President of Clinical Development, Ophthalmology at Eloxx. In this role, she leads the development of potential therapies for Inherited Retinal Disorders. Dr. Schneider has nearly 15 years of experience in drug development while serving as Chief Medical Officer at ThromboGenics (now Oxurion), Vice President and Therapeutic Area Head of Retina and Glaucoma at Allergan, Vice President Retina, at Acucela, Sr. Medical Director at GlaxoSmithKline, Director, Clinical and Scientific Affairs for Ophthalmology at Bausch & Lomb, Vice President and Chief Medical Officer, US Clinical Affairs at Santen, and Medical Director at Genentech. While at Genentech, she worked extensively on the ranibizumab program. Dr. Schneider received her medical degree from the Medical College of Pennsylvania. She completed her ophthalmology residency at the Medical College of Virginia and her fellowship training in ocular oncology at Thomas Jefferson Wills Eye Hospital and in ophthalmic pathology at The Johns Hopkins Wilmer Eye Institute.